Eli Lilly and Company $LLY Stock Position Trimmed by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. trimmed its position in Eli Lilly and Company (NYSE:LLY) by 2.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 544,492 shares of the company’s stock after selling 13,167 shares during the quarter. Eli Lilly and Company comprises 22.0% of Goelzer Investment Management Inc.’s holdings, making the stock its largest position. Goelzer Investment Management Inc. owned approximately 0.06% of Eli Lilly and Company worth $415,447,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Lazard Freres Gestion S.A.S. grew its holdings in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after acquiring an additional 41,222 shares during the period. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares in the last quarter. Central Pacific Bank Trust Division grew its stake in shares of Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after purchasing an additional 1,843 shares during the period. Capital Advisors Inc. OK increased its holdings in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares in the last quarter. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,076.38 on Tuesday. The business has a 50 day simple moving average of $965.92 and a two-hundred day simple moving average of $833.56. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.66, a PEG ratio of 1.08 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 earnings per share. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Updated clinical data released for Lilly’s breast cancer programs and the EMBER‑3 Phase 3 update for imlunestrant indicate meaningful progress on oncology/gynecologic pipelines, supporting long‑term revenue diversification beyond obesity. Read More.
• Positive Sentiment: Bank of America and other sell‑side activity remain constructive: BofA keeps a Buy on LLY (with a modest PT change) and Goldman raised a price target, signaling continued analyst conviction that obesity launches will drive earnings growth into 2027 and beyond. Read More.
• Positive Sentiment: Media and pundit attention (Jim Cramer) is highlighting a major catalyst for Lilly—continued commercialization and new indications for weight‑loss and other specialty drugs—which can attract retail flows and support multiple expansion. Read More.
• Positive Sentiment: Deal chatter: reports that Lilly met French officials and related market moves (Abivax) suggest Lilly is actively pursuing partnerships/licensing that could add pipeline value if deals materialize. Read More.
• Positive Sentiment: Technical/momentum signals note LLY trading near its 52‑week high, which can attract momentum traders and algos ahead of upcoming earnings and regulatory milestones. Read More.
• Neutral Sentiment: Market commentary pieces (Zacks, JP Morgan preview) are drawing attention to Lilly’s valuation, guidance and upcoming catalysts; useful for framing expectations but not immediate price movers. Read More. Read More.
• Neutral Sentiment: Analyst notes on biotech peers (CRISPR Therapeutics) mention a partnership with Lilly; this validates Lilly’s external R&D strategy but is secondary to Lilly’s own drug launches. Read More.
• Negative Sentiment: Regulatory setback for Lilly’s obesity franchise competitively: the FDA approved Novo Nordisk’s Wegovy oral pill—the first daily oral obesity drug—giving Novo a first‑mover advantage in the oral obesity market and adding near‑term competitive pressure on Lilly’s oral candidate (orforglipron). This is the primary headwind in today’s tape. Read More.

Analysts Set New Price Targets

Several research firms recently commented on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 15th. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a research report on Thursday, December 4th. Finally, Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, December 16th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.